1,271 results on '"Guo, Hongqian"'
Search Results
2. A novel pelvis-prostate model BPPP predicts immediate urinary continence after Retzius-sparing robotic-assisted laparoscopic radical prostatectomy
3. Targeted gene sequencing reveals disparate genomic mutations between young and older adults in renal cell carcinoma
4. PD-L1 expression and its correlation with tumor biomarkers in Chinese urothelial bladder cancer
5. A PSMA PET/CT-based risk model for prediction of concordance between targeted biopsy and combined biopsy in detecting prostate cancer
6. Prediction of false-positive PI-RADS 5 lesions on prostate multiparametric MRI: development and internal validation of a clinical-radiological characteristics based nomogram
7. Modified Retzius-sparing robot-assisted radical prostatectomy for cases with anterior tumor: a propensity score-matched analysis
8. Highly accurate and effective deep neural networks in pathological diagnosis of prostate cancer
9. Multi-cohort validation of Ascore: an anoikis-based prognostic signature for predicting disease progression and immunotherapy response in bladder cancer
10. Impact of operator expertise on transperineal free-hand mpMRI-fusion-targeted biopsies under local anaesthesia for prostate cancer diagnosis: a multicenter prospective learning curve
11. The impact of a second MRI and re-biopsy in patients with initial negative mpMRI-targeted and systematic biopsy for PIRADS ≥ 3 lesions
12. Clinical study on laparoscopic minimally invasive surgery and transumbilical single-port laparoscopic surgery in the treatment of benign ovarian tumours and its influence on ovarian functions
13. Performance of 18F-FDG PET/MRI and its parameters in staging and neoadjuvant therapy response evaluation in bladder cancer
14. Which Patients with Prostate Cancer and Lymph Node Uptake at Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography Scan Are at a Higher Risk of Prostate-specific Antigen Persistence After Radical Prostatectomy? Identifying Indicators of Systemic Disease by Integrating Clinical, Magnetic Resonance Imaging, and Functional Imaging Parameters
15. Robot-assisted Simple Enucleation Versus Standard Robot-assisted Partial Nephrectomy for Low- or Intermediate-complexity, Clinical T1 Renal Tumors: A Randomized Controlled Noninferiority Trial
16. Prediction of T staging in PI-RADS 4–5 prostate cancer by combination of multiparametric MRI and 68Ga-PSMA-11 PET/CT
17. ALOX5 deficiency contributes to bladder cancer progression by mediating ferroptosis escape
18. Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects
19. Combination of robot-assisted laparoscopy and ureteroscopy for the management of complex ureteral strictures
20. WDR4 promotes the progression and lymphatic metastasis of bladder cancer via transcriptional down-regulation of ARRB2
21. Estrogen associates with female predominance in Xp11.2 translocation renal cell carcinoma
22. Prognostic Significance of Grade Discrepancy Between Primary Tumor and Venous Thrombus in Nonmetastatic Clear-cell Renal Cell Carcinoma: Analysis of the REMEMBER Registry and Implications for Adjuvant Therapy
23. Effect of extensive artery isolation during robotic-assisted partial nephrectomy on blood pressure of patients with poorly controlled hypertension: a preliminary study
24. Convolutional neural network based deep-learning architecture for intraprostatic tumour contouring on PSMA PET images in patients with primary prostate cancer
25. MIOX inhibits autophagy to regulate the ROS -driven inhibition of STAT3/c-Myc-mediated epithelial-mesenchymal transition in clear cell renal cell carcinoma
26. LINC00926 promotes progression of renal cell carcinoma via regulating miR-30a-5p/SOX4 axis and activating IFNγ-JAK2-STAT1 pathway
27. Identification of the Optimal Candidates for Nodal Staging with Extended Pelvic Lymph Node Dissection Among Prostate Cancer Patients Who Underwent Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography. External Validation of the Memorial Sloan Kettering Cancer Center and Briganti Nomograms and Development of a Novel Tool
28. Mitochondrial-targeted brequinar liposome boosted mitochondrial-related ferroptosis for promoting checkpoint blockade immunotherapy in bladder cancer
29. Prognostic and immunological role of Asporin across cancers and exploration in bladder cancer
30. Is There an Impact of Transperineal Versus Transrectal Magnetic Resonance Imaging–targeted Biopsy on the Risk of Upgrading in Final Pathology in Prostate Cancer Patients Undergoing Radical Prostatectomy? An European Association of Urology-Young Academic Urologists Prostate Cancer Working Group Multi-institutional Study
31. Correction to: Overdiagnosis and stage migration of ISUP 2 disease due to mpMRI-targeted biopsy: facts or fictions
32. Celastrol recruits UBE3A to recognize and degrade the DNA binding domain of steroid receptors
33. 68Ga-PSMA-11 PET/CT Parameter Correlates with Pathological VEGFR-2/PDGFR-β Expression in Renal Cell Carcinoma Patients
34. Environmental microcystin exposure triggers the poor prognosis of prostate cancer: Evidence from case-control, animal, and in vitro studies
35. Prediction of immune infiltration and prognosis for patients with urothelial bladder cancer based on the DNA damage repair-related genes signature
36. Validation of Epstein criteria and development of a nomogram for active surveillance in a contemporary Chinese population
37. Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT)
38. [68Ga]Ga-PSMA-11 PET/CT has potential application in predicting tumor HIF-2α expression and therapeutic response to HIF-2α antagonists in patients with RCC
39. Negative Pressure Wound Therapy for Patients With Complicated Mucocutaneous Separation Following Ileal Conduit Urinary Diversion: A Case Series
40. Trans‐rectovesical pouch urethral‐sparing robotic‐assisted simple prostatectomy: A case series
41. PROact: A prospective phase II study to evaluate olaparib plus abiraterone and prednisone combination therapy in patients with metastatic hormone sensitive prostate cancer with HRR gene mutation.
42. Patient-reported outcomes (PROs) for rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy (ADT) in high-volume, metastatic, hormone-sensitive prostate cancer (mHSPC): An analysis of the CHART randomized, open-label, phase 3 trial.
43. Follow-up on Patients with Initial Negative mpMRI Target and Systematic Biopsy for PI-RADS ≥3 Lesions – An EAU-YAU Study Enhancing Prostate Cancer Detection.
44. MP31-01 OPTIMIZING DETECTION AND PREDICTION OF PROSTATE CANCER AFTER POSITIVE MRI AND NEGATIVE BIOPSIES
45. PD17-07 CAN WE RELY ON AVAILABLE MODELS PREDICTING PATHOLOGICAL OUTCOMES IN PROSTATE CANCER PATIENTS STAGED WITH 68GA PSMA-PET/CT? EXTERNAL VALIDATION OF THE EXISTING NOMOGRAMS FOR EXTRACAPSULAR EXTENSION AND SEMINAL VESICLE INVASION AND DEVELOPMENT OF A NOVEL TOOL INCLUDING INTRAPROSTATIC SUVMAX
46. PD51-01 PLASMA tsRNAs AS NOVEL DIAGNOSTIC BIOMARKERS FOR RENAL CELL CARCINOMA
47. PD45-05 WHEN DOES SYSTEMATIC BIOPSY INFORMATION MATTER THE MOST? IDENTIFYING INDEPENDENT PREDICTORS OF DISEASE DOWNGRADING AT RADICAL PROSTATECTOMY IN HIGH GRADE PROSTATE CANCER BASED ON A LARGE MULTI-INSTITUTIONAL SERIES
48. PD61-03 EXTERNAL VALIDATION OF THE AVAILABLE NOMOGRAMS FOR THE IDENTIFICATION OF CANDIDATES FOR a STAGING EXTENDED PELVIC LYMPH NODE DISSECTION AT THE TIME OF RADICAL PROSTATECTOMY IN PROSTATE CANCER PATIENTS PREOPERATIVELY STAGED WITH PSMA PET
49. MP19-19 THE IMPACT OF MULTIPLE LESIONS IN PROSTATE MRI-INSIGHTS FROM THE YAU PROSTATE CANCER GROUP
50. MP19-15 THE SIGNIFICANT ADDED VALUE OF CONCOMITANT SYSTEMATIC PROSTATE BIOPSIES IN ADDITION TO TARGETED SAMPLING IN PATIENTS WITH PREVIOUS NEGATIVE BIOPSIES. IMPLICATIONS FOR ACCURATE STAGING PREDICTIONS FROM A LARGE MULTI-INSTITUTIONAL SERIES
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.